桂敏,顾秋云,胡雨森,等.益生菌联合铋剂四联疗法治疗幽门螺杆菌感染的临床观察[J].上海预防医学,2024,36(5):482-487.. DOI: 10.19428/j.cnki.sjpm.2024.23598
引用本文: 桂敏,顾秋云,胡雨森,等.益生菌联合铋剂四联疗法治疗幽门螺杆菌感染的临床观察[J].上海预防医学,2024,36(5):482-487.. DOI: 10.19428/j.cnki.sjpm.2024.23598
GUI Min,GU Qiuyun,HU Yusen,et al.Clinical effects of probiotics combined with bismuth quadruple therapy for Helicobacter pylori infected patients[J].Shanghai Journal of Preventive Medicine,2024,36(05):482-487.. DOI: 10.19428/j.cnki.sjpm.2024.23598
Citation: GUI Min,GU Qiuyun,HU Yusen,et al.Clinical effects of probiotics combined with bismuth quadruple therapy for Helicobacter pylori infected patients[J].Shanghai Journal of Preventive Medicine,2024,36(05):482-487.. DOI: 10.19428/j.cnki.sjpm.2024.23598

益生菌联合铋剂四联疗法治疗幽门螺杆菌感染的临床观察

Clinical effects of probiotics combined with bismuth quadruple therapy for Helicobacter pylori infected patients

  • 摘要:
    目的 探究益生菌联合铋剂四联疗法(BQT)对幽门螺杆菌(HP)阳性患者的临床疗效、胃肠道不良反应的改善和肠道菌群的影响。
    方法 选取2023年5月—2023年7月在上海市第一人民医院消化内科就诊的HP阳性患者,随机分成2组,每组40人。益生菌组予以益生菌和标准BQT法2周,停药后口服益生菌4周。安慰剂组予以益生菌安慰剂和标准BQT法2周,BQT停药后口服益生菌安慰剂4周。采用13C尿素呼气试验评估临床疗效,运用胃肠道症状评定量表评估干预前后患者的胃肠道不良反应,使用微生物多样性16S rDNA测序技术检测干预前后患者的肠道菌群水平。
    结果 2组的根除率差异无统计学意义(P>0.05)。干预前,益生菌组和安慰剂组胃肠道症状评定量表各项评分无统计学差异(P>0.05)。干预后益生菌组和安慰剂组患者反酸评分为1.10±0.30 vs 1.35±0.53(P<0.05),胃或腹部饥饿时疼痛评分为1.07±0.26 vs 1.30±0.52(P<0.05)。益生菌组自身前后对比发现,益生菌组患者干预后腹痛(1.24±0.44 vs 1.58±0.71,P<0.05)、胃或腹部饥饿时疼痛(1.07±0.26 vs 1.27±0.45,P<0.05)和大便干硬(1.24±0.49 vs 1.48±0.75,P<0.05)评分显著低于益生菌组干预前。
    结论 益生菌联合BQT在一定程度上可改善药物治疗过程中的胃肠道不良反应和肠道菌群紊乱,且对HP的根除率无影响。

     

    Abstract:
    Objective To investigate the effects of probiotics combined with bismuth quadruple therapy (BQT) on clinical efficacy、gastrointestinal adverse reactions and intestinal flora in Helicobacter pylori (HP) positive patients.
    Methods The patients who were positive for HP from May 2023 to July 2023 in the department of gastroenterology of Shanghai first people's hospital were randomly divided into 2 groups with 40 people in each group. The probiotic group was given 2 weeks of quadruple therapy with probiotics and standard BQT, followed by 4 weeks of oral probiotics after quadruple discontinuation. The placebo group was given 2 weeks of probiotic placebo and standard BQT, followed by 4 weeks of oral probiotic placebo. 13C urea breath test was used to evaluate the clinical efficacy, gastrointestinal symptoms rating Scale was used to evaluate the gastrointestinal adverse reactions of patients before and after the intervention, and microbial diversity 16S rDNA sequencing technology was used to detect the level of intestinal flora of patients before and after the intervention.
    Results There was no significant difference in the eradication rate between the two groups (P>0.05). Before the intervention, there was no significant difference in the scores of the gastrointestinal symptom rating scale between the probiotic group and the placebo group. After the intervention, patients in the probiotic group had significantly lower pain scores on acid reflux (1.10±0.30 vs 1.35±0.53, P<0.05) and stomach or abdominal hunger than in the placebo group (1.07±0.26 vs 1.30±0.52, P<0.05). Through the before-and-after comparison of the probiotic group, the scores of abdominal pain (1.24±0.44 vs 1.58±0.71, P<0.05), stomach or abdominal hunger (1.07±0.26 vs 1.27±0.45, P<0.05) and dry and hard stool (1.24± 0.49 vs 1.48±0.75,P<0.05) were significantly lower in the probiotic group than before the intervention in the probiotic group.
    Conclusion Probiotics combined with BQT can improve the gastrointestinal adverse reactions and intestinal flora disorders in the process of quadruple drug therapy, but it does not improve the eradication rate of HP.

     

/

返回文章
返回